The need for new antifungal agents is undeniable. Current therapeutic choices for the
treatment of invasive fungal infections are limited to three classes of drugs. Most used …

In recent years their has been an increased use of antifungal agents and has resulted in the
development of resistance to drugs. Currently, use of standard antifungal therapies can be …

Computational analysis of biosynthetic gene clusters (BGCs) has revolutionized natural
product discovery by enabling the rapid investigation of secondary metabolic potential within …

This review is an updated and expanded version of a paper that was published in this
journal in 1997. The time frame has been extended in both directions to include the 22 years …

A single-source reference on the biology of algae, the third edition of Algae: Anatomy,
Biochemistry, and Biotechnology examines the most important taxa and structures for …

Covering: 31st December 2004Natural product and natural product-derived compounds that
are being evaluated in clinical trials or in registration (current 31 December 2004) have …

This article provides a perspective on the current status of drug therapy for invasive fungal
diseases, together with priorities for the future development of novel compounds. Key …

Introduction Candida albicans is the most prevalent fungal pathogen in humans. Due to the
development of drug resistance, there is today a need for new antifungal agents for the …

A secondary metabolite is a chemical compound produced by a limited number of fungal
species in a genus, an order, or even phylum. A profile of secondary metabolites consists of …

Even though significant advances have been made in understanding microbial diversity,
most microorganisms are still only characterized by'molecular fingerprints' and have resisted …